The 7 most recent market catalysts affecting $APVO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Aptevo Expects To Enter Investigational New Drug-Enabling Studies For Its Lead Candidate APVO451 In H1 2027
Aptevo Therapeutics is providing an update on its next-generation trispecific immuno-oncology programs, specifically stating that its lead candidate, APVO451, is expected to enter …
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 75
Aptevo Therapeutics Reports 93% Clinical Benefit Rate in Key Leukemia Trial
Aptevo Therapeutics reported a 93% clinical benefit rate for its drug mipletamig in a triplet therapy for frontline acute myeloid leukemia (AML) patients with TP53 mutations. This …
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 75
Aptevo Reports 93% Clinical Benefit Rate With Mipletamig Triplet in Evaluable Frontline Acute Myeloid Keukemia Patients With TP53 Mutations
Aptevo Therapeutics reported a 93% clinical benefit rate for its Mipletamig triplet in frontline acute myeloid leukemia patients with TP53 mutations. This is a significant positive…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED COMPOSITIONS, AND METHODS".
Aptevo Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering 'TUMOR-ASSOCIATED ANTIGENS AND CD3-BINDING PROTEINS, RELATED …
Aug 24, 2026
Corporate Catalyst
Neutral
Impact 55
Watching Aptevo Therapeutics; Zacks Small-Cap Research Gives Stock $30 Price Valuation
The headline signals a positive development for Aptevo Therapeutics (APVO) due to a $30 price valuation from Zacks Small-Cap Research. This could lead to increased investor interes…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 65
Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPE
Aptevo Therapeutics has closed two financing activities: a warrant inducement transaction and a private placement (PIPE). In the warrant inducement, existing warrant holders exerci…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 65
Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline
Aptevo Therapeutics has filed a patent application for a novel Nectin-4 x PD-L1 dual-targeting backbone, which is central to its new solid tumor strategy. This move is significant …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.